*SRX Global And CERO 1236, A Wholly-Owned SPV, Enter Into Definitive Agreement To Acquire CERo Therapeutics, An Innovative Cellular Immunotherapy Company Developing CER 1236 For Hematologic Malignancies >SRXH

Dow Jones · 1d ago

Please log in to view news